At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 100 enrolled
Drug / intervention
Vitamin Ddrug
Likely dose
Vitamin D 100.000 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Double Blind Placebo Controlled Trial With Vitamin D to Prevent Bronchiolitis Obliterans Syndrome After Lung Transplantation
In Brief
A Phase 4 clinical trial evaluating Vitamin D for Allograft Rejection and 2 related conditions. Completed, enrolled 100 participants across 1 site.
Detailed Summary
Vitamin D deficiency occurs in around 50% of our transplant population. Preventive treatment with Vitamin D (D-cure) can reduce the prevalence of Bronchiolitis Obliterans Syndrome after lung transplantation
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium
CollaboratorsKU Leuven
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2010
Enrollment StartOct 2010
Primary CompletionSep 2013
Study CompletionAug 2015
TodayJul 2026
First PostedSep 30, 2010
Enrollment StartOct 1, 2010
Primary CompletionSep 1, 2013
Study CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 15.8 years ago
Interventions
Vitamin Ddrug
Every month 100.000 units of vitamin D in syringe Exacta-Med Oral Dispenser during 2 years and re-evaluation after 3 years